🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with figures suggesting over 82 million instances per year. Particularly high rates are seen in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, alternatively called a brand name, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

Based on results published in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The research enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Clinicians directly involved have voiced positive views. Having a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.